EGFR-TKIs resistance via EGFR-independent signaling pathways.

about

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells.Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA

P2860

Q55491850-07E1C15E-2BB9-4945-B3F9-7EAB7CB36FBE Q57489971-F17931B9-7221-40D7-90F8-BBD26EBD3E50

P2860

EGFR-TKIs resistance via EGFR-independent signaling pathways.

Item

http://www.wikidata.org/entity/Q49887890

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@en

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@nl

type

Item

label

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@en

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@nl

prefLabel

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@en

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@nl

P1476

EGFR-TKIs resistance via EGFR-independent signaling pathways.

@en

P2093

Qian Liu

http://www.w3.org/2001/XMLSchema#string

Shengnan Yu

http://www.w3.org/2001/XMLSchema#string

Shuang Qin

http://www.w3.org/2001/XMLSchema#string

Weiheng Zhao

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera

Cell signaling by receptor tyrosine kinases

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

P2888

s12943-018-0793-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S12943-018-0793-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kongming Wu

Qian Chu

P577

2018-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101066794

http://www.w3.org/2001/XMLSchema#string

P698

29455669

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

5817859

http://www.w3.org/2001/XMLSchema#string

EGFR-TKIs resistance via EGFR-independent signaling pathways.

about

P2860

P2860

EGFR-TKIs resistance via EGFR-independent signaling pathways.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932